First-line treatment of acute lymphoblastic leukemia with pegasparaginase

Riccardo Masetti, Andrea PessionPediatric Oncology and Hematology Unit &ldquo;Lalla Ser&agrave;gnoli&rdquo;, University of Bologna, Bologna, ItalyAbstract: Acute lymphoblastic leukemia (ALL) accounts for almost 4000 cases annually in the United States, approximately two third...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Riccardo Masetti, Andrea Pession
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/81f7070976174f1ab286e5142a130eb8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:81f7070976174f1ab286e5142a130eb8
record_format	dspace
spelling	oai:doaj.org-article:81f7070976174f1ab286e5142a130eb82021-12-02T02:01:10ZFirst-line treatment of acute lymphoblastic leukemia with pegasparaginase1177-54751177-5491https://doaj.org/article/81f7070976174f1ab286e5142a130eb82009-07-01T00:00:00Zhttp://www.dovepress.com/first-line-treatment-of-acute-lymphoblastic-leukemia-with-pegasparagin-a3338https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Riccardo Masetti, Andrea PessionPediatric Oncology and Hematology Unit &ldquo;Lalla Ser&agrave;gnoli&rdquo;, University of Bologna, Bologna, ItalyAbstract: Acute lymphoblastic leukemia (ALL) accounts for almost 4000 cases annually in the United States, approximately two thirds of which are in children and adolescents. Treatment results of ALL have improved considerably in the past decade, due to an optimal stratification of patients and a rational use of different antileukemic agents among which L-asparaginase (L-ASNase) plays a fundamental role. This drug has been used in pediatric ALL chemotherapy protocols for almost 3 decades. In the 1970s and 1980s a chemically modified form of this enzyme called pegasparaginase (PEG-ASNase) was rationally synthesized to decrease immunogenicity of the enzyme and prolong its half-life. The different advantages of PEG-ASNase have been demonstrated in many clinical studies, the last of which underline the utility of this drug in front-line therapy of ALL. In this review, we discuss the pharmacological advantages and clinical potential of PEG-ASNase and its important use in first-line treatment of ALL.Keywords: pegasparaginase, acute, lymphoblastic leukemia, pegylation Riccardo MasettiAndrea PessionDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 359-368 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Riccardo Masetti Andrea Pession First-line treatment of acute lymphoblastic leukemia with pegasparaginase
description	Riccardo Masetti, Andrea PessionPediatric Oncology and Hematology Unit &ldquo;Lalla Ser&agrave;gnoli&rdquo;, University of Bologna, Bologna, ItalyAbstract: Acute lymphoblastic leukemia (ALL) accounts for almost 4000 cases annually in the United States, approximately two thirds of which are in children and adolescents. Treatment results of ALL have improved considerably in the past decade, due to an optimal stratification of patients and a rational use of different antileukemic agents among which L-asparaginase (L-ASNase) plays a fundamental role. This drug has been used in pediatric ALL chemotherapy protocols for almost 3 decades. In the 1970s and 1980s a chemically modified form of this enzyme called pegasparaginase (PEG-ASNase) was rationally synthesized to decrease immunogenicity of the enzyme and prolong its half-life. The different advantages of PEG-ASNase have been demonstrated in many clinical studies, the last of which underline the utility of this drug in front-line therapy of ALL. In this review, we discuss the pharmacological advantages and clinical potential of PEG-ASNase and its important use in first-line treatment of ALL.Keywords: pegasparaginase, acute, lymphoblastic leukemia, pegylation
format	article
author	Riccardo Masetti Andrea Pession
author_facet	Riccardo Masetti Andrea Pession
author_sort	Riccardo Masetti
title	First-line treatment of acute lymphoblastic leukemia with pegasparaginase
title_short	First-line treatment of acute lymphoblastic leukemia with pegasparaginase
title_full	First-line treatment of acute lymphoblastic leukemia with pegasparaginase
title_fullStr	First-line treatment of acute lymphoblastic leukemia with pegasparaginase
title_full_unstemmed	First-line treatment of acute lymphoblastic leukemia with pegasparaginase
title_sort	first-line treatment of acute lymphoblastic leukemia with pegasparaginase
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/81f7070976174f1ab286e5142a130eb8
work_keys_str_mv	AT riccardomasetti firstlinetreatmentofacutelymphoblasticleukemiawithpegasparaginase AT andreapession firstlinetreatmentofacutelymphoblasticleukemiawithpegasparaginase
_version_	1718402788034084864

First-line treatment of acute lymphoblastic leukemia with pegasparaginase

Ejemplares similares